Children’s Hospital of Philadelphia (CHOP) announced today that it has been awarded a five-year up to $38.9 million award from the Advanced Research Projects Agency for Health (ARPA‑H) THRIVE program to support the advancement of personalized gene therapy. The award will fund work led by Rebecca Ahrens-Nicklas, MD, PhD, Director of CHOP’s Gene Therapy for Inherited Metabolic Disorders Frontier Program, and Lindsey A. George, MD, CHOP’s Director of Clinical In Vivo Gene Therapy and an attending physician in the Division of Hematology, together with colleagues and partner institutions, including Kiran Musunuru, MD, PhD, MPH, ML, MRA, Co-Director of the Orphan Disease Center (ODC), a partnership between CHOP and Penn Medicine. THRIVE is led by ARPA-H Program Manager Daria Fedyukina, Ph.D.
The ARPA-H award, which builds on the historic treatment of baby KJ Muldoon, whose first ever personalized gene-editing therapy was led by Ahrens-Nicklas and Musunuru, will focus on the development of individualized gene-editing therapies for four groups of rare, liver‑related genetic disorders. These include urea cycle disorders (dangerous newborn ammonia buildup), organic acidemias (toxic metabolites and metabolic crises in infants), severe blood clotting (e.g. protein C deficiency), and bleeding (e.g. hemophilia A) disorders. The CHOP‑led team proposed a carefully designed program to turn a real-time, personalized gene‑editing approach into a scalable platform to treat infants and children with rare, life‑threatening liver‑related genetic diseases, while managing safety, regulatory, manufacturing, and access challenges.
“Current care for these patients typically requires lifelong special diets, regular infusions, or liver transplants, which carry big risks and delays. Tragically, many infants die or have major morbidity before a treatment is possible,” said Ahrens-Nicklas. “Formal clinical trials are needed to evaluate if gene editing therapies are safe and if they work.”
The five-year plan is organized into three core components. CHOP will build and refine its base editing and prime editing lipid nanoparticle systems to create reliable tools for precise gene correction. CHOP will carry out clinical trials, pursue regulatory approvals, engage payers, and expand treatment access by implementing therapies at community sites and remote hubs.
“We are excited to pursue this work and to contribute to the broader goal of advancing the development of transformative individualized gene editing therapies,” said George.
Featured in this article
Experts
Specialties & Programs
Research
Children’s Hospital of Philadelphia (CHOP) announced today that it has been awarded a five-year up to $38.9 million award from the Advanced Research Projects Agency for Health (ARPA‑H) THRIVE program to support the advancement of personalized gene therapy. The award will fund work led by Rebecca Ahrens-Nicklas, MD, PhD, Director of CHOP’s Gene Therapy for Inherited Metabolic Disorders Frontier Program, and Lindsey A. George, MD, CHOP’s Director of Clinical In Vivo Gene Therapy and an attending physician in the Division of Hematology, together with colleagues and partner institutions, including Kiran Musunuru, MD, PhD, MPH, ML, MRA, Co-Director of the Orphan Disease Center (ODC), a partnership between CHOP and Penn Medicine. THRIVE is led by ARPA-H Program Manager Daria Fedyukina, Ph.D.
The ARPA-H award, which builds on the historic treatment of baby KJ Muldoon, whose first ever personalized gene-editing therapy was led by Ahrens-Nicklas and Musunuru, will focus on the development of individualized gene-editing therapies for four groups of rare, liver‑related genetic disorders. These include urea cycle disorders (dangerous newborn ammonia buildup), organic acidemias (toxic metabolites and metabolic crises in infants), severe blood clotting (e.g. protein C deficiency), and bleeding (e.g. hemophilia A) disorders. The CHOP‑led team proposed a carefully designed program to turn a real-time, personalized gene‑editing approach into a scalable platform to treat infants and children with rare, life‑threatening liver‑related genetic diseases, while managing safety, regulatory, manufacturing, and access challenges.
“Current care for these patients typically requires lifelong special diets, regular infusions, or liver transplants, which carry big risks and delays. Tragically, many infants die or have major morbidity before a treatment is possible,” said Ahrens-Nicklas. “Formal clinical trials are needed to evaluate if gene editing therapies are safe and if they work.”
The five-year plan is organized into three core components. CHOP will build and refine its base editing and prime editing lipid nanoparticle systems to create reliable tools for precise gene correction. CHOP will carry out clinical trials, pursue regulatory approvals, engage payers, and expand treatment access by implementing therapies at community sites and remote hubs.
“We are excited to pursue this work and to contribute to the broader goal of advancing the development of transformative individualized gene editing therapies,” said George.
Recommended reading
Marking One-Year Anniversary of World’s First Personalized CRISPR Gene Therapy
February 25, 2026 marks one year since KJ, an infant born with severe carbamoyl phosphate synthetase 1 deficiency, became the world’s first person to receive a personalized CRISPR-based gene editing therapy.
New FDA Plausible Mechanism Framework Spurs Development of Personalized In Vivo Prime Editing Platform for Urea Cycle Disorders
Researchers at CHOP, Penn Medicine and partners report a customizable in vivo prime-editing platform to treat infantile-onset urea cycle and other liver genetic diseases.
Contact us
Ashley Moore
Gene Therapy for Inherited Metabolic Disorders Program